GLPG Galapagos NV

Galapagos receives transparency notification from FMR LLC

Galapagos receives transparency notification from FMR LLC

Mechelen, Belgium; 23 December 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.

Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 22 December 2022 from FMR LLC, who notified that it holds 3,884,633 of Galapagos’ voting rights, consisting of 3,884,633 ordinary shares. FMR LLC controls investment funds Fidelity Management & Research Company LLC, FIAM Holdings LLC, Fidelity Management Trust Company and Strategic Advisers LLC, of which Fidelity Management & Research Company LLC increased its position to 3,367,506 voting rights, Fidelity Management Trust Company increased its position to 500,070 voting rights and Strategic Advisers LLC decreased its position to 510 voting rights. Hence, the first-mentioned controlled undertaking of the FMR LLC group individually crossed above the 5% threshold. FMR LLC's holding of 3,884,633 Galapagos' voting rights, including its controlled undertakings’ holdings, represents 5.90% of Galapagos' currently outstanding 65,835,511 shares. FMR LLC thus remains above the 5% threshold of Galapagos’ voting rights. The full transparency notice is available on the Galapagos website.

About Galapagos

Galapagos is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. For additional information, please visit or follow us on  or .

Contact

Investors:

Sofie Van Gijsel

Head of Investor Relations

Sandra Cauwenberghs

Director Investor Relations

3

Media:

Marieke Vermeersch

Head of Corporate Communication



1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market

 

Attachment



EN
23/12/2022

Underlying

GLPGGalapagos NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galapagos NV

Jacob Mekhael
  • Jacob Mekhael
GLPG GALAPAGOS NV

Galapagos Signs agreement with Gilead on T-cell Engager in autoimmune ...

Galapagos announced that, following Gilead entering into a definitive agreement to acquire Ouro Medicines for $1,675m in cash consideration, and up to $500m in contingent milestone payments, Galapagos and Gilead have now entered into a binding agreement to collaborate on advancing gamgertamig (BCMAxCD3 T cell engager) in autoimmune diseases. This agreement comes after the companies announced their advanced discussions on the collaboration last week. Economically, Galapagos is effectively co-fina...

03/31/26 March 31, 2026 1 EN
Guy Sips ... (+4)
  • Guy Sips
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Wim Lewi
UCB UCB S.A.
AGFB AGFA-GEVAERT NV
GLPG GALAPAGOS NV
IVA INVENTIVA SA
WDP WAREHOUSES DE PAUW SCA
MAAT MAAT PHARMA SA
ONWD ONWARD MEDICAL NV
03/31/26 March 31, 2026 1 EN
 PRESS RELEASE
Free
GLPG GALAPAGOS NV

Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerkin...

Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibiliteit voor Galapagos op  Na deze transactie blijft de Vennootschap over het grootste deel van haar liquide middelen beschikken voor bijkomende strategische transacties en andere prioriteiten van kapitaalallocatie Kans om met gamgertamig een potentieel first-in-class & best-in-class T-cell-engager in auto-immuunziekten te ontwikkelen ...

March 31, 2026 1 EN
 PRESS RELEASE
Free
GLPG GALAPAGOS NV

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Ad...

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos  Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 20...

March 31, 2026 1 EN
 PRESS RELEASE
Free
GLPG GALAPAGOS NV

Galapagos Announces Nomination of Gino Santini to its Board of Directo...

Galapagos Announces Nomination of Gino Santini to its Board of Directors Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine  Mr. Santini will bring extensive corporate governance, business development and industry leadership experience to the Board Mechelen, Belgium; March 26, 2026, 21:02 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the proposed appointment of Gino Santini as a Non-Executive Independent Director, with the intention to appoint him as Chair of its Board of Directors, subject to shareholder...

March 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch